AtriCure reports Q2 adjusted EPS (2c), consensus (16c)

Reports Q2 revenue $136.1M, consensus $130.26M. “Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particularly in our AtriClip platform and cryoSPHERE device offerings. We’re seeing increasing momentum as our new technologies drive deeper adoption, reduced procedure times, and improved patient outcomes,” said Michael Carrel, President and Chief Executive Officer at AtriCure (ATRC). “With this foundation, we’re excited about the opportunities ahead in the second half of 2025 and beyond to continue delivering strong growth and expanding profitability.”